Exchange Traded Concepts LLC Buys Shares of 5,793 Glaukos Co. (NYSE:GKOS)

Exchange Traded Concepts LLC acquired a new position in shares of Glaukos Co. (NYSE:GKOS) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,793 shares of the medical instruments supplier’s stock, valued at approximately $755,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Inspire Investing LLC boosted its position in shares of Glaukos by 6.9% during the third quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock worth $416,000 after buying an additional 206 shares during the period. Valeo Financial Advisors LLC boosted its position in shares of Glaukos by 9.8% during the third quarter. Valeo Financial Advisors LLC now owns 7,877 shares of the medical instruments supplier’s stock worth $1,026,000 after buying an additional 700 shares during the period. Private Advisory Group LLC acquired a new position in shares of Glaukos during the third quarter worth about $878,000. GAMMA Investing LLC boosted its position in shares of Glaukos by 44.7% during the third quarter. GAMMA Investing LLC now owns 1,725 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 533 shares during the period. Finally, Handelsbanken Fonder AB boosted its position in shares of Glaukos by 30.4% during the third quarter. Handelsbanken Fonder AB now owns 14,600 shares of the medical instruments supplier’s stock worth $1,902,000 after buying an additional 3,400 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Glaukos

In other news, Director Aimee S. Weisner sold 25,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now owns 30,119 shares in the company, valued at approximately $3,614,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now owns 30,119 shares in the company, valued at $3,614,280. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Marc Stapley sold 6,250 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the transaction, the director now owns 34,076 shares in the company, valued at approximately $4,291,190.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,250 shares of company stock worth $4,825,873. Company insiders own 6.40% of the company’s stock.

Glaukos Price Performance

NYSE:GKOS opened at $133.40 on Friday. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19. The stock’s 50 day moving average price is $128.08 and its two-hundred day moving average price is $116.64. The firm has a market capitalization of $6.72 billion, a price-to-earnings ratio of -46.17 and a beta of 1.02. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $136.60.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.52). The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The firm’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.55) earnings per share. On average, analysts anticipate that Glaukos Co. will post -2.18 earnings per share for the current year.

Wall Street Analyst Weigh In

GKOS has been the subject of several recent research reports. Citigroup cut Glaukos from a “buy” rating to a “neutral” rating and increased their price target for the company from $130.00 to $132.00 in a research report on Wednesday, July 10th. Needham & Company LLC increased their price target on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. StockNews.com cut Glaukos from a “hold” rating to a “sell” rating in a research report on Friday, August 30th. BTIG Research increased their price target on Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Finally, Truist Financial increased their price target on Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a research report on Monday, October 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $130.45.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.